scPharmaceuticals Inc. (NASDAQ:SCPH) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET

Company Participants

PJ Kelleher – LifeSci Advisors

John Tucker – Chief Executive Officer

Steve Parsons – Senior Vice President of Commercial

Rachael Nokes – Chief Financial Officer

John Mohr – Senior Vice President, Clinical Development and Medical Affairs

Conference Call Participants

Glen Santangelo – Jefferies

Roanna Ruiz – SVB Securities

Stacy Ku – TD Cowen

Douglas Tsao – H.C. Wainwright

Nazibur Rahman – Maxim Group

Operator

Greetings, and welcome to the scPharmaceuticals First Quarter 2023 Earnings Conference Call. At this time, all participants are in listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host, PJ Kelleher from LifeSci Advisors. Thank you. Please go ahead, sir.

PJ Kelleher

Thank you, operator. Before turning the call over to management, I would like to make the following remarks concerning forward-looking statements. All statements on this conference call, other than historical facts, are forward-looking statements within the meaning of the federal securities laws including, but not limited to statements regarding scPharmaceuticals expected future financial results and management’s expectations and plans for the business and FUROSCIX.

The words anticipate, believe, estimate, expect, intend, guidance, confidence, target, project and other similar expressions are used to typically to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance and may involve and are subject to certain risks and uncertainties and other important factors that may affect scPharmaceuticals business, financial condition and other operating results.

These include, but are not limited to, the risk factors and other qualifications contained in scPharmaceuticals Annual Report on Form 10-K, quarterly reports on Form 10-Q and other reports filed by the company with the SEC to which your attention is directed. Actual outcomes and results may differ materially from what is expressed or implied by these forward-looking statements.

Any forward-looking statements made in this conference call, including responses to your questions are based on current expectations as of today, and scPharmaceuticals expressly disclaims any intent or obligation to update these forward-looking statements except as required by law.

It is now my pleasure to turn the call over to Mr. John Tucker, Chief Executive Officer of scPharmaceuticals. John?

John Tucker

Thank you, PJ, and thanks to everyone listening to this afternoon’s call and webcast. This afternoon, I am pleased to provide an operational update before turning the call over to Steve Parsons, our Senior Vice President of Commercial for more detailed update on the early stages of the FUROSCIX launch, and then Rachael Nokes, our Chief Financial Officer for a review of our financials. We will then open the call up for your questions.